Researchers have looked at the physiology of baker's yeast in bread dough as it ferments, revealing adaptations over time as its environmental conditions change. (Image © amit erez/ iStock.) 4
In bread dough, yeast cells of several types suffer severe osmotic stress, but baker's yeast completes the task with far fewer changes in its transcriptome than in those of either of two other strains of Saccharomyces cerevisiae, confırming that the former is more highly adapted to bread making, according to Elham Aslankoohi of VIB Laboratory of Systems Biology in Leuven, Belgium, and her collaborators. Details appear in the December 2013 Applied and Environmental .
While other researchers investigated yeast cells in liquid media, this study is the fırst to examine the yeast transcriptome under the solid-state conditions they experience within bread dough, according to Aslankoohi. "This is an important difference because the solid matrix of dough presents cells with specifıc challenges that are not present, or that are at least different, in a liquid environment," she says. "The low water activity and restricted molecular movement in dough implies that cells encounter osmotic stress, and that there may be gradients in concentrations of nutrients, toxic metabolites, and even heat."
Moreover, despite extensive analysis of yeast over many decades, "surprisingly little" was known about the physiology of yeast cells during bread fermentation "because the cells are literally buried in the dough matrix," Aslankoohi adds. "We optimized a protocol to isolate high-quality yeast RNA from fermenting dough, which allowed us to investigate the gene activity of the cells throughout the 3-hour leavening process.
"Yeast cells make dramatic changes in their transcriptome to adapt to the dough as their environment, and to activate the fermentation process," she continues. Initially, "cells respond to an osmotic shock that is likely caused by the low water activity in the dough. In the second stage, the cells have adapted to the new solid environment, and start fermenting the available sugars. Towards the end, the cells suffer from nutrient depletion and show signs of increased stress."
For all three yeast strains, the greatest changes in the transcriptome are linked to the high-osmolarity glycerol (HOG) pathway, suggesting that those changes are regulated through this pathway, says Aslankoohi. Additionally, deleting genes that are in the HOG pathway or that are among its main targets impaired the fermentation process.
Applying transcriptomics to solidstate fermentations by yeast "advances the fıeld," says Rachel J. Dutton of Harvard University in Cambridge, Mass. She praises the VIB researchers for also conducting mutational analysis while comparing evolutionarily distinct strains. "These are simple systems, and therefore can be very powerful in terms of the level of analysis they allow," she says. "Solid-state fermentations are responsible for production of many fermented foods, as well as medically and industrially important products. Therefore, understanding the factors that may limit growth could help improve control over these processes."
Although microbiology is facing the "tragedy of overflowing knowledge," it dares not succumb to the "temptation of simplicity," says Fernando Baquero, who was keynote speaker during the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy held in Denver last September. He joined other microbiologists who spoke during other sessions bemoaning the diffıculties in identifying novel means for combatting infectious diseases. He and they are not shirking that challenge, even if they are espousing nontraditional ways to address it.
"We should not be looking for 'ideal' antibiotics," continues Baquero, who is from the Ramón y Cajal Institute for Health Research in Madrid, Spain. Amid an "exponential growth of knowledge," the numbers of new drugs to be anticipated remains "extremely low." Even so, "we don't have a shortage of antibiotics on the table," he adds, chiding doomsayers who say the war is lost to microbial pathogens because of rampant drug resistance.
Yet, in the "twilight of big antibiotics," drug resistance is real, and coping with it requires fresh thinking, according to Baquero. "Why not use many antimicrobial drugs in one patientadjusted to each patient and each epidemic?" he asks. After all, oncologists pursue just this kind of "personalized therapy" in patients with cancer, who are routinely treated with multiple drugs, while "no one says anything. Why not with antibiotics? Why not use many substances to treat patients at many levels, including with agents having high toxicity and high cost?"
Other microbiologists are voicing similar views, including several who spoke during the symposium "Anti-Infective Therapy in the 21st Century:
Target the Host!" "We need to think disruptively and challenge dogma," says one of them, Brad Spellberg, of the Harbor UCLA Medical Center in Torrance, Calif. He takes issue with the widely held view that it is preferable to treat infected patients with bactericidal rather than bacteriostatic drugs. "We want therapies to slow the bugs down; if there's slower killing, there's less resistance," he says. There are "lots of examples in which rapid killing [of the microbial pathogens] harms the patients."
One test for this approach involves using the chelating agent transferrin "to starve bugs," including several bacterial and fungal pathogens, slowing their growth and allowing the immune system of infected mice to mop up, according to Spellberg. Another is to determine whether agents that can block lipopolysaccharides (LPS), an outer-membrane component of many gram-negative bacterial pathogens, can protect mice against disease, albeit in the presence of viable bacteria, he says.
In casting another dogma aside, Andrew Tomaras of Pfızer in Cambridge, Mass., recommends looking at particular pathogens in specifıc physiologic states and anatomic niches. In one such site, the lungs, bacterial pathogens already face a carbon nutrient shortage, but some of them make do with phospholipids, which are plen- tiful there, he says. With that setting in mind, he and his collaborators reevaluated a substantial library of compounds, looking for "hidden gems" that might inhibit steps in the glyoxylate shunt, a carbon-scavenging metabolic pathway that is "unique to bacteria, and not found in plants or animals." From that shelved set of some 150,000 compounds, Tomaras and his collaborators identifıed candidates belonging to 3 to 5 classes, several of which prove to be decent inhibitors of two separate enzyme-catalyzed steps in that metabolic pathway. Although none of those inhibitors is "optimized," the effort so far suggests there is value in taking this different approach to screening and identifying potentially useful antimicrobial agents, he says.
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Targeting Type III Secretion To Combat P. aeruginosa
Shannon Weiman
The Pseudomonas aeruginosa type III secretion system (T3SS) injects exoenzymes into host neutrophils, macrophages, and lymphocytes-impairing their functions while promoting infection, according to several researchers who presented their fındings during the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in Denver last September. In response, host-cell pattern recognition receptors detect the T3SS apparatus, a virulence factor common to many gram-negative pathogens, and generate inflammatory cytokines that damage host tissues. Targeting T3SS or thwarting downstream effects may provide an alternative antimicrobial strategy to traditional antibiotics.
"Exoenzymes can interfere with host cell mechanisms and induce apoptosis once injected into target cells," says Alexis Broquet of the University of Nantes, France, who presented fındings during the poster session "Antimicrobial Resistance and Immune Therapy of Experimental Infection." T3SS exoenzymes contribute to P. aeruginosa virulence by inducing apoptosis in neutrophils, depleting these crucial defenders in the lungs and bronchial lavage fluid of mice, he says. "Type-III virulence factor deletion dampens acute lung injury and restores the survival of infected animals." Although the mortality rate of the wild-type PAO1 bacterial strain in mice is 50%, mutant strains that no longer produce T3SS exoenzymes or lack its injection apparatus are avirulent and do not induce neutrophil apoptosis.
T3SS also activates inflammasomes through the Nod-like receptor 4 (NLRC4), according to Emelie Faure of the Lille Teaching Hospital, France, who presented fındings during the same poster session. "NLRC4-inflammasome activation [is] deleterious for the host in a murine acute lung infection model with increased lung injury and decreased bacterial clearance," she says. These deleterious effects are due in part to inflammatory cytokines, which can be blocked by IL-18 binding protein (IL-18BP), she reports. "IL-18BP-treated mice compared with controls had signifıcantly increased survival (80 vs. 20% at 96 hours), decreased lung injury, and decreased weight loss." Moreover, IL-18BP treatment enhances bacterial clearance by promoting an early Th17-like response, which leads to increased expression of antimicrobial peptides in the lungs.
Another approach is to identify inhibitors of the T3SS injection apparatus itself, says Donald Moir, chief scientifıc offıcer of Microbiotix in Worcester, Mass., who shared his group's fındings during the poster session "Targeting the Gram-Negative Outer Membrane." "Without T3SS, many pathogenic bacteria are unable to cause disease, making this apparatus an attractive target for novel antimicrobial drugs," he says.
His group identifıed fıve smallmolecule inhibitors in three chemical classes, with phenoxyacetamides exhibiting the highest potency and selectivity to date. One such highly stereoselective agent rescues mammalian cells from P. aeruginosa infection in vitro. "T3SS inhibitors will be administered therapeutically and prophylactically in combination with anti-pseudomonal agents to enhance bacterial eradication by potentiating the host's innate immune system and improving the antibacterial activity of co-admin-
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Polio Cases in Syria, Isolates in Israel Prompt Broad Responses
At least seven countries in the Middle East are participating in a special vaccination campaign as part of a broad response to an outbreak of polio in Syria, with 13 confirmed cases as of November 2013, according to officials of the World Health Organization (WHO) in Geneva, Switzerland. The supplementary immunization program calls for vaccinating 1.6 million children against polio as well as several other diseases of childhood. Although focused on Syria, the immunization campaign will encompass neighboring countries, reflecting in part the need to cope with refugees fleeing the civil war in that country. In a related development, despite no human cases of polio appearing in Israel, the country is continuing its own supplementary immunization campaign that began last February after officials found wild polio virus in samples from sewage treatment facilities and, later, in stool samples from 42 carriers of the virus, all of whom had been fully vaccinated with the inactivated polio virus vaccine. istered antibiotics," Moir says. These inhibitors are also effective in vitro against other gram-negative pathogens with this apparatus, including Yersinia and Chlamydia species.
Antibodies also can block T3SS, protecting mice against lethal infection, according to Paul Warrener of MedImmune in Gaithersburg, Md., who spoke during the 2012 ICAAC in San Francisco. He and his colleagues developed a monoclonal antibody against the PcrV protein of the injectosome complex, which blocks exoenzymes being injected in vitro and protects mice against pneumonia. A similar antibody is being evaluated in clinical trials.
Shannon Weiman is a freelance writer in San Francisco, Calif.
RESEARCH ADVANCES
Neutralizing Vacuoles of C. albicans Can Tame Its Virulence Carol Potera
When the vacuoles of Candida albicans cells are made less acidic, this fungal pathogen becomes less virulent and potentially more manageable as an infectious agent, according to Rajini Rao of Johns Hopkins University School of Medicine in Baltimore, Md., and her collaborators. Details appeared July 24, 2013 in the Journal of Biological Chemistry (doi:10.1074/jbc.M113. 494815).
Mutants of C. albicans that lack V-ATPase, a proton pump, are avirulent and cannot form fılaments needed for infection, Rao says. V-ATPase also plays a role in protein processing, metabolite transport, biofılm formation, and other cellular activities. Faced with these many functions of V-ATPase and its several subunits, she and her collaborators focused on two isoforms of subunit a, called VPH1 and STV1. "Mutations that knock out all V-ATPase activity would not provide insight into what specifıc function is critical for virulence," she explains.
Acidifying vacuoles of this yeast depends exclusively on VPH1. When Rao and her group evaluated mutants lacking either VPH1 or STV1, they found that VPH1 is critical for forming hyphae, which are critical for virulence. These fılaments are reduced by up to 85% in mutants lacking VPH1 and which cannot acidify vacuoles. The importance of this subunit for virulence was further tested in experiments involving mice. Thus, injecting wild-type C. albicans as well as mutants lacking STV1 into mice kills nearly all of them within a week. In contrast, mice injected with mutants lacking VPH1 remain healthy.
These fındings validate V-ATPase and vacuolar acidifıcation as a potential drug target, according to Rao. "Drugs known to alter the pH of vacuoles could render Candida harmless while potentially posing little risk to infected patients," she says. "The next step is to screen drugs already approved for humans to fınd others that block vacuole acidifıcation."
Rao and her collaborators learned several years ago that amidarone, a drug for treating heart arrhythmia, can block acidifıcation of fungal vacuoles. Moreover, she says, the antifungal drug fluconazole, which blocks ergosterol biosynthesis, also impairs V-ATPase and makes fungal vacuoles less acidic.
When C. albicans-infected mice are treated with amidarone by itself, the animals show modest improvement. However, when amidarone is combined with fluconazole, the infection is reduced more effectively than when such mice are treated by fluconazole alone. Details of these experiments appeared June 3, 2010 in PLoS Pathogens [doi:10.1371/journal.ppat.1000939].
"This is the fırst signifıcant attempt to dissect the importance of vacuolar acidifıcation for C. albicans virulence," says microbiologist David S. Perlin of New Jersey Medical School/Rutgers in Newark, N. J. "Because we have very few classes of antifungal drugs, exploring this virulence target is worthwhile." Cell death programs, also known as apoptosis, can trigger herpesviruses to replicate, including any of four known human herpesviruses that can remain latent in their hosts for extended periods, according to Steven Zeichner of Children's National Medical Center and George Washington University in Washington, D.C., and his collaborators. Because so many humans are infected by one or more herpesvirusesincluding cytomegalovirus, oral herpes simplex virus-1 (HSV-1) and genital herpes simplex virus-2 (HSV-2), and Varicella zoster, which causes chicken pox and shingles-this apoptosis-activation pathway could have broad clinical signifıcance. Moreover, it might help to explain some of the side effects of several widely used anticancer drugs, he and his collaborators point out. Details appear in the October 2013 Journal of Virology (87:10641-10650).
These studies began with Zeichner following up fındings that high concentrations of the antibiotic doxycycline can induce apoptosis and also activate replication by the Kaposi's sarcoma-associated herpesvirus (KSHV). In other words, apoptosis triggers an "alternative replication pathway" for this virus, he says. Similarly, he adds, apoptosis also triggers replication of HSV-1, citing research by his former mentor, Bernard Roizman of the University of Chicago.
"We decided to test . . . several additional human herpesviruses that cause notable diseases and which have good latent infection cell line models, including human herpesvirus (HHV)-6A, -6B, and -7, and Epstein-Barr virus (EBV)," Zeichner says. Several widely used cytotoxic drugs, including doxorubicin and vincristine, act in part by inducing apoptosis of malignant cells. In doing so, they also can activate EBV, KSHV, and several additional herpesviruses, he fınds. Perhaps patients being treated with such drugs, who are harboring latent herpesviruses, also should be treated with antiviral agents, he and his colleagues note.
Additionally, prednisone, a widely used steroid anti-inflammatory agent, may activate latent herpesviruses through apoptosis, according to Zeichner. For example, some patients with Kaposi's sarcoma become worse following treatment with this drug or similar glucocorticoids. Instead of acting via immunosuppression, such drugs might be reactivating KSHV.
"It was intriguing to learn that steroids might activate herpesviruses due to apoptosis instead of immunosuppression, as is widely believed," says Dharam Ablashi of the HHV-6 Foundation in Santa Barbara, Calif. "Perhaps herpesvirus reactivation is responsible for some of the organ failure and severe complications that occur during the late flare of symptoms that occurs in these patients."
Zeichner's report "does not address whether shingles may arise through this mechanism-a fascinating possibility," Ablashi says. Oral and genital herpes may also flare due to apoptosis. In any case, understanding the mechanism of reactivation via apoptosis, he says, "will be the fırst step towards developing novel approaches to treat such conditions in a rational manner."
Amid this interest, several researchers expressed doubts to the HHV-6 Foundation about whether the cell lines used for Zeichner's study carry latent herpesviruses. Sharing those concerns, Ablashi advises Zeichner to redo his experiments with different cell lines. Although Zeichner disagrees, saying the cells that he used contain latent virus and that other researchers report similar fındings, he does plan
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Novel Antimicrobial Candidates
Recent reports on novel antimicrobial candidates include several compounds that are active against drug-resistant strains of bacterial pathogens: 
RESEARCH ADVANCES
For Cells, Mistakes Repairing DNA Speed Evolution Marcia Stone
Bacterial cells mutate rapidly and specifıcally-not merely randomly-in response to stress, says Susan Rosenberg at Baylor College of Medicine in Houston, Tex., who seeks to tweak the core principles of evolution-namely, that evolution-driving mutations arise randomly, constantly, gradually, and independently of selective environments. "Stress-induced mutations are different; they're controlled by [specifıc] stress-response programs that invite error-prone DNA-break repair and are only activated when cells are maladapted to their environments-in other words, are stressed." She spoke at a Presidential Research Seminar, sponsored by Memorial Sloan-Kettering Cancer Center in New York, N.Y., last October. "Stress-induced mutations quickly increase genetic diversity, enabling subsets of resistant cells to survive and perpetuate their genotype, thereby saving the strain from extinction," Rosenberg continues. Starved Escherichia coli cells, for example, activate the RpoS stress response that allows error-prone polymerases to repair double-strand DNA breaks. The resulting mutation flood accelerates evolution, Rosenberg contends. She speculates that RpoS-promoted mutagenic break repair evolved because of its value as an evolutionary engine.
Error-prone DSB-repair proteins appear to trigger stress-induced mutations in circumstances other than star-vation and in organisms other than E. coli. "We know that RpoS programs are induced by osmotic, pH, temperature, and oxidative stresses," says Rosenberg. "We also have evidence that when confronted by antibiotics, E. coli activates RpoS-encoded DSB-repair proteins similar to those used by starved cells, and that pathogenic Salmonella induces RpoS-dependent mutations in response to bile, a membrane irritant." Additionally, Pseudomonas aeruginosa biofılms display a DSB-repair, proteingenerated diversity that she suspects arises by the same mechanisms.
The ability of cells to change rapidly when stressed is also important to tumor progression in hypoxic environments because it provides a way for malignant cells to develop resistance to anti-cancer therapies, according to Rosenberg. She calls for the development of "anti-evolution" drugs that block stress-promoted cellular adaption to host-instigated stressors. These new agents could be combined with conventional antibacterial, antifungal, and anti-cancer drugs, all of which should be classed together as "anti-proliferatives," she says. Details of her arguments appeared August 22, 2012 in Bioessays (34: 885-892; doi:10.1002/ bies.201200050) .
"Rosenberg and colleagues identify specifıc mechanisms enabling bacteria to switch into a hypermutable state, turning up the frequency with which adaptive mutations occur," says Lance Price at George Washington University in Washington, D.C., who was not involved in this research. "More specifically, they explain how the hypermutable state is regulated. It's very cool.
"However, this still feels Darwinian because while the responses to stressors may be specifıc, the mutations themselves appear to be randomly generated," Price continues. "Importantly, the intrinsic ability of bacteria to quickly deal with stress helps explain why exposure to subtherapeutic doses of some antibiotics leads to such rapid evolution of resistant mutants and why the practice has proved so dangerous in
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Recently Noted "Rare" Events of Microbiology
Here are some examples of recently noted rare events in microbiology:
• Plant genes encoding expansins, which weaken cell walls, are a "rare example" of genes that were transferred from plants to bacteria The MAREDAT data set will be useful for biogeography, biodiversity, and marine ecology studies, among others, according to Vogt of ETH Zürich. "We do not know very much about ocean ecosystems in general, due to sampling issues, [and] do not know exactly who lives where and why," she says. "Since plankton plays an important role for global biogeochemical cycles and other important marine ecosystem services such as food and resource provision, it is essential that we understand how these ecosystems work, and how they may be affected by anthropogenic climate change, overfıshing, and coastal eutrophication." "A big surprise to me from reviewing the data was how low the biomass of coccolithophores (phytoplankton calcifıers) was, considerably lower than the zooplankton calcifıers (pteropods and foraminifers)," says Erik Buitenhuis of the University of East Anglia in Norwich, UK, another coordinator of the project. "I continue to be astonished at how little we know about the biosphere that we depend on for our survival and well-being, and that we continue to treat it with carelessness as if we had several other biospheres to use up." "The MAREDAT plankton atlas is a useful resource for both researchers and educators in oceanography," says Tammi L. Richardson of the University of South Carolina in Columbia, S.C., who was not involved in the MARE-DAT effort. "While the intended user group is the community of ecosystem modelers, this atlas would also be of immense value to scientists who are in the initial stages of writing a proposal and wish to choose a study site with a specifıc plankton community composition to test hypotheses. I can also see this volume being a wonderful teaching tool for students." Barry E. DiGregorio is a freelance writer in Middleport, N.Y.
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New Antibody Could Counteract Muscle Wasting, Boosting Strength in Patients with Cachexia, COPD
Cachexia afflicts many with cancer, chronic obstructive pulmonary disease (COPD), and sporadic inclusion body myositis, a rare disease occurring in people over 50, and some elderly suffer from similar muscle wasting known as sarcopenia. Now David Glass and Estelle Trifılieff of Novartis, Cambridge, Mass. USA, have developed an antibody that could counteract wasting by boosting muscle mass and strength in these people. The new compound, BYM338, acts to prevent muscle wasting by blocking a receptor that engages a cellular signaling system that puts the brakes on muscle development when appropriate. Sometimes those signals are active when they should not be. "Our goal was to release the brakes," says Glass.
"A variety of signals . . . can activate the receptor," says Glass. Prior to development of BYM338, compounds developed to block these molecules were blunt instruments, either trapping all incoming signals, which stimulated muscle growth but also caused harmful side effects, or blocking a single receptor activator, providing only tepid muscle growth stimulation. BYM338 was successfully designed to occupy the Goldilocks zone-just right. In animal studies, it boosted muscle mass 25-50%, "with recipients also gaining strength," says Glass. And in human tissue culture studies, skeletal muscle myofıbers grew noticeably thicker. BYM338 also blocked loss of muscle caused by pro-atrophy stimuli such as glucocorticoids.
Sarcopenia afflicts 5-13% of those aged 60 -70, rising to 11-50% in individuals over 80 years old, says Glass. In cancer patients, cachexia can interfere with ability to undergo chemotherapy. A quarter of patients with chronic ob-structive pulmonary disease suffer from cachexia, which can worsen their already dire respiratory diffıculties. Clinical trials are underway for COPD, cancer cachexia, and recruitment is ongoing for sarcopenia. compared to 30 years ago," says Adlerberth. "It is known that gut microbiota of high complexity suppresses C. diffıcile growth and toxin production. That is why treatment with broad-spectrum antibiotics is a risk factor for C. diffıcile disease." The investigators warn that prevalence of toxigenic C. diffıcile bacteria in the gut of infants and young children "provides ample opportunity for spread to individuals at risk for C. diffıcile disease." (I. Adlerberth, H. Huang, A. Weintraub, et al, 2013. Toxin-producing Clostridium difficile strains as long-term gut colonizers of healthy infants. J. Clin. Microbiol. Online ahead of print 30 October 2013 , doi: 10.1128 NEW from
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